AHA Comments to CMS on GLOBE Payment Model

Why It Matters

The GLOBE model could dramatically reshape Medicare drug pricing and hospital drug spend, making regulatory clarity essential for providers and patients.

Key Takeaways

• AHA backs price‑lowering but warns of operational gaps
• Model may increase hospitals' administrative burden
• Calls for monitoring Part B drug acquisition costs
• Seeks protections against expanded white‑bagging practices
• Emphasizes need for clear CMS implementation guidance

Pulse Analysis

The Global Benchmark for Efficient Drug Pricing (GLOBE) model represents the latest federal effort to curb soaring prescription costs within Medicare Part B. By anchoring payments to most‑favored‑nation prices, CMS aims to align U.S. drug spending with international benchmarks while offering lower out‑of‑pocket expenses for selected beneficiaries. This policy shift follows years of legislative pressure to address drug price inflation, and it signals a more aggressive stance on cost containment across the Medicare program.

The American Hospital Association’s response underscores practical concerns that could surface once the model rolls out. Hospitals worry that the lack of detailed operational guidance may translate into complex reporting requirements, heightened negotiations with manufacturers, and potential disruptions to existing pharmacy workflows. A particular focus is on white‑bagging—a practice where specialty drugs are shipped directly from third‑party pharmacies to clinical sites—which could increase if providers seek to meet the model’s pricing thresholds. The AHA’s call for CMS to monitor acquisition costs and institute protections aims to prevent these unintended burdens from eroding the model’s intended savings.

If CMS integrates the AHA’s recommendations, the GLOBE model could set a precedent for future Medicare payment reforms, balancing price reductions with feasible implementation for health systems. Clear guidance would help hospitals adapt supply‑chain processes, preserve patient access, and maintain financial stability. Conversely, ambiguous rules risk amplifying administrative overhead and could trigger legal challenges, potentially slowing nationwide adoption. Stakeholders across the pharmaceutical and healthcare sectors will be watching closely as CMS finalizes the rule, given its implications for drug pricing dynamics, hospital budgeting, and overall Medicare sustainability.